Pfizer Inc. (PFE)
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma's oral drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk's blockbuster weight loss injection Wegovy, but the pill is still in early-stage development.
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved guidance, targeting $61–$64 billion in 2025 revenue and $3–$3.15 adjusted EPS, while managing leverage post-acquisitions. Patent expirations threaten $17–$18 billion in annual revenue by 2026–2028, but aggressive acquisitions, R&D investments and cost savings aim to offset losses and drive long-term growth.
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.
Pfizer: The Market Is Still Wrong About It
Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventy‑six percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025)
Shares of Pfizer ( NYSE: PFE ) gained 3.69% over the past month after gaining 9.90% the month prior.
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
